Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022
April 08, 2022 13:00 ET
|
Monte Rosa Therapeutics, Inc.
– Data Highlight Essential Role of GSPT1 in Sustaining Myc-induced Translational Addiction in Solid Tumors – BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE),...
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
March 29, 2022 07:30 ET
|
Monte Rosa Therapeutics, Inc.
– Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 – – Progressed NEK7 and CDK2 Molecular Glue Degrader Programs into Lead Optimization –...
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
February 03, 2022 16:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company...
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
January 25, 2022 07:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON and REHOVOT, Israel, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, announced a...
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 07:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company...
Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
December 02, 2021 07:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced the promotion of...
Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021 07:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its...
Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates
November 10, 2021 07:30 ET
|
Monte Rosa Therapeutics, Inc.
– Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1 – – Presented Preclinical Data at AACR-NCI-EORTC Highlighting...
Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit
October 20, 2021 07:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon...
Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
October 07, 2021 09:00 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue-based precision medicines, today announced preclinical...